Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

Vincenza Conteduca, Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and social problem. The expanding knowledge of HCV lifecycle has led to the development of novel antiviral agents that: a) specifically target a viral function (direct-acting antivirals), or b) specifically inhibit viral replication. The present review describes the novel anti-HCV drugs that have been better studied at the time of this writing and the current two types of treatment, namely interferon-based and interferon-free regimens. In addition, predictive factors, virological responses, side-effects, and resistance mechanisms of the novel agents are summarized. Conclusions: The introduction of novel antiviral agents is remarkably changing the therapeutic combinations aimed at improving virological responses both for easy-to-cure and difficult-to-treat patients. Since additional, effective drugs are under advanced development, it seems reasonable to expect that further therapeutic and prognostic improvements will be achieved in the near future.

Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalJournal of Infection
Volume68
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • BOC
  • CHC
  • Chronic hepatitis C
  • CV
  • DAA
  • Direct-acting antivirals
  • DVR
  • ERVR
  • EVR
  • Gt
  • Gts
  • HCV
  • Host-targeting antivirals
  • HTAs
  • IFN-α
  • IL28B
  • Interferon
  • ISGs
  • NIs
  • NNIs
  • PI
  • PIFN
  • Protease inhibitors
  • RBV
  • RGR
  • Ribavirin
  • RVR
  • SNP
  • SoC
  • SVR
  • TPV

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents'. Together they form a unique fingerprint.

Cite this